Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice? Export

@article{citeulike:3173542, abstract = {10.1182/blood-2008-05-155465}, author = {Smolej, Lukas}, citeulike-article-id = {3173542}, citeulike-linkout-0 = {http://dx.doi.org/10.1182/blood-2008-05-155465}, citeulike-linkout-1 = {http://bloodjournal.hematologylibrary.org/cgi/content/abstract/112/5/2167}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/18725576}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=18725576}, day = {1}, doi = {10.1182/blood-2008-05-155465}, journal = {Blood}, keywords = {cll}, month = {September}, number = {5}, pages = {2167+}, posted-at = {2008-08-29 16:48:38}, priority = {2}, title = {Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?}, url = {http://dx.doi.org/10.1182/blood-2008-05-155465}, volume = {112}, year = {2008} }

TY - JOUR ID - citeulike:3173542 L3 - citeulike-article-id:3173542 N2 - 10.1182/blood-2008-05-155465 IS - 5 JF - Blood TI - Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice? VL - 112 SP - 2167 KW - cll AU - Smolej, Lukas PY - 2008/09/01/ UR - http://dx.doi.org/10.1182/blood-2008-05-155465 ER -